Abstract
BACKGROUND: Medulloblastoma, an aggressive but potentially curable CNS disease, remains a treatment challenge due to the biological heterogeneity of the disease. Analysis of actionable targets can provide opportunities in the development of curative therapies. To identify potential candidate genes, we investigated alterations in a cohort of medulloblastoma patients.